StockData
10x Genomics, Inc. logo

10x Genomics, Inc. (TXG) company profile

TXGNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/30118% above fair value
$58.19−0.91 (-1.54%)

Close on Nov 13, 2026Market cap $7.58BP/E –Yield –

About 10x Genomics

Laboratory Analytical Instruments, SIC 3826

10x Genomics, Inc. is a life sciences technology company that develops integrated solutions to interrogate and analyze biological systems. Its product portfolio spans instruments, consumables, and software across single-cell analysis and spatial biology platforms. The single-cell offering, anchored by the Chromium system, partitions samples into barcoded components for high-throughput multiomic readouts. The spatial biology portfolio features the Visium and Xenium platforms, which enable tissue-scale spatial transcriptomics and in situ optical imaging of gene expression without conventional sequencing. A complementary software ecosystem, including pipeline and visualization tools, supports experimental planning, data processing, and analysis. The company primarily serves academic, government, biotechnology, and biopharmaceutical research institutions.

The company operates globally, selling its products in more than 50 countries through direct sales organizations and third-party distribution partners. It maintains certified manufacturing operations across facilities in Pleasanton, California, Singapore, and Taiwan, while outsourcing instrument assembly to qualified contract manufacturers. The company employs over 1,100 personnel across research, commercial, and operational functions. Its principal executive offices are located in Pleasanton, California.

Summary of the business section of 10x Genomics's latest annual report, written by StockData.

Company profile

Company

Legal name
10x Genomics, Inc.
Founded
2012
Headquarters
Pleasanton, CA
Address
6230 Stoneridge Mall Road 94588
Phone
(925) 401-7300
Employees
1,178, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Jose, California

Stock & identifiers

Ticker
TXG
Exchange
Nasdaq
IPO date
Sep 12, 2019
Shares outstanding
130M, Jul 31, 2026
Public float
$1.30B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1770787
CUSIP
88025U109
ISIN
US88025U1097
FIGI
BBG007WX14X0
Share class FIGI
BBG007WX14Y9
LEI
5493003Z6741WNLG7H43
EIN
45-5614458

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Serge SaxonovChief Executive Officer, Director4,122,758
Benjamin J. HindsonSee Remarks, Director488,182
Adam TaichChief Financial Officer330,098
Ansuman SatpathyDirector–
Joseph E. GilliamDirector31
Shehnaaz SulimanDirector23,792
John R. StuelpnagelDirector328,436
Sarah A. TeichmannDirector28,058
Kimberly J. PopovitsDirector37,445
Alan MateoDirector85,877
Sridhar KosarajuDirector68,278

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.33M$6.79M$2.76M$12$125
FY2024$7.93M-$21.17M$4.40M$10$93
FY2023$8.29M$17.35M$3.40M$40$94
FY2022$18.81M-$14.31M$9.38M$26$90
FY2021$11.70M$20.81M$4.98M$105$100
FY2020$10.88M$55.28M$6.51M$186$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsIncentive payTotalvs. prior year
Serge Saxonov
Chief Executive Officer
$674.25K$5.02M$634.73K$6.33M-20%
Adam S. Taich
Chief Financial Officer
$507.46K$1.44M$284.58K$2.23M-32%
Benjamin J. Hindson
President and Chief Scientific Officer
$518.65K$1.79M$292.95K$2.60M-39%
Eric S. Whitaker
Former Chief Legal Officer
$518.65K$2.63M$292.95K$3.44M-51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Sep 12, 2019
Offer price
$39.00
Securities offered
10,000,000
Gross proceeds
$390.00M
Exchange
Nasdaq
First trading day
Sep 12, 2019
First-day close
$52.75+35.3%
Lock-up ends (est.)
Mar 10, 2020

“The initial public offering price is $39.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed a total of 1,178 individuals, 822 of whom were employed in the United States and 356 of whom were employed outside the United States.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?